⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519397 | 0.73 | — | — | |
| SCHEMBL6754460 | 0.69 | — | — | |
| SCHEMBL9397725 | 0.69 | — | — | |
| SCHEMBL2016777 | 0.69 | — | — | |
| SCHEMBL5122347 | 0.67 | — | — | |
| SCHEMBL1783296 | 0.65 | F2 (0.40) | — | |
| SCHEMBL18289219 | 0.64 | — | — | |
| SCHEMBL24754464 | 0.60 | — | — | |
| SCHEMBL22431138 | 0.60 | ALDH1A1 (0.30) | — | |
| SCHEMBL25132425 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1846394-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| EP-0665843-B1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6194436-B1 | THERAPY FOR LUNG CANCER | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| US-5990125-A | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5837711-A | Substituted quinuclidines as substance P antagonists | PFIZER INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0861831-A1 | HETEROARYL-SUBSTITUTED ACRYLOYLGUANIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5569662-A | ANTIINFLAMMATORY AGENT, GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, ANTIASTHMA AGENTS, ANALGESICS | PFIZER INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0665843-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0632809-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994010170-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993019064-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1993-09-30 | — | — | WO | disclosed |